A lack of evidence is behind the NHS' decision to withhold a breakthrough prostate cancer drug from patients who have already been treated using another new generation drug, Nice said.
A spokeswoman for Nice said the committee were unable to "draw any conclusions" about what would happen if "milestone" enzalutamide was used by prostate cancer sufferers who had also taken abiraterone.
In the trial data provided by the manufacturer of enzalutamide none of the patients had received previous treatment with abiraterone, therefore the committee was not able to draw any conclusions about the effectiveness of enzalutamide after previous abiraterone treatment, and this is reflected in the recommendations.
We would welcome any additional data the manufacturer of enzalutamide can provide.
More top news
The poll comes ahead of a debate in the House of Commons on Friday on a new Bill which would introduce such a system in England.
Jobs with decent pay and flexibility are "few and far between" for single parents who are the main earner and carer, said the report.
Coal's share of the power mix had fallen to 7%, while wind climbed to new highs to provide 15% of the country's electricity.